icd 10 semaglutide What ICD-10 (International Classification of Diseases, 10th Revision) code can I use to get Wegovy (semaglutide) approved for a patient with obesity? Diabetes Mellitus Coding Explained |

Try the BMI Calculator Table of contents The coverage split: diabetes vs weight loss How UnitedHealthcare structures GLP-1 coverage across plan types The prior authorization requirements you'll face What most articles get wrong about "medical necessity" The employer exclusion problem Brand-name vs compounded: coverage differences How to check your specific plan's coverage The step-therapy protocol UnitedHealthcare requires Out-of-pocket costs when coverage is approved What to do when your claim is denied The Medicare Advantage exception FAQ Sources The coverage split: diabetes vs weight loss UnitedHealthcare treats GLP-1 medications as two separate drug categories depending on the diagnosis code your provider submits: For Type 2 diabetes (ICD-10 code E11.x): Ozempic (semaglutide), Mounjaro (tirzepatide), Trulicity (dulaglutide), and Victoza (liraglutide) are typically Tier 3 or Tier 4 covered medications Prior authorization required but approval rates exceed 75% when BMI and A1C criteria are met Rybelsus (oral semaglutide) covered on most formularies as alternative to injectable options For obesity or weight management (ICD-10 code E66.x): Wegovy (semaglutide) and Zepbound (tirzepatide) are excluded on approximately 60% of employer-sponsored UnitedHealthcare plans When covered, placed on specialty tier (Tier 4 or 5) with 25-40% coinsurance Saxenda (liraglutide 3.0 mg) has slightly higher coverage rates than Wegovy or Zepbound but still excluded on many plans The critical distinction: the FDA-approved indication determines coverage, not the medication itself

What form does GLP-3RT come in

Another murine study reported that ipamorelin reduced bone loss by increasing mineralization in test animals exposed to corticosteroids, compared to controls [18]

Click the image below to access your free download of a sample from the State Of Healthcare 2024 GLP-1 agonists are also a central theme of our 2024 State of Healthcare

Presented for research literature review only Strange RC et al

He said, there aren't many times in a lifetime where you know you're right and you know you really have an investment that's going to work